NovaGo Therapeutics secures USD 30 million in Series B financing led by Neurimmune and Pureos to advance a proof-of-concept study for acute spinal cord injury.
Amount Raised
$30 Million
Round Type
Series B
ZurichBiotechnologyHealth CareTherapeuticsInvestors
Description
NovaGo Therapeutics announced the completion of a CHF 24 million (USD 30 million) Series B financing round, led by Neurimmune and Pureos. The funding will be utilized to advance its lead program into a proof-of-concept study in patients with acute spinal cord injury. This study is designed to enroll 120 patients across sites in Germany, Spain, and Switzerland. The financing round also includes contributions from existing and new investors, complemented by non-dilutive funding from two foundations.
Quick answer
NovaGo Therapeutics raised $30 Million in a Series B round, dated September 2, 2026. Investors: Pureos and Neurimmune. NovaGo Therapeutics is based in Zurich, Switzerland.
- How much did NovaGo Therapeutics raise?
- NovaGo Therapeutics raised $30 Million in a Series B round on September 2, 2026.
- Who invested in NovaGo Therapeutics?
- Pureos and Neurimmune are named as investors in this round.
- What does NovaGo Therapeutics do?
- NovaGo Therapeutics AG is a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system.
- Where is NovaGo Therapeutics based and how big is it?
- NovaGo Therapeutics is based in Zurich, Switzerland. Fundz records about 2 employees.
- Who are the decision-makers at NovaGo Therapeutics?
- Fundz holds 2 contacts at NovaGo Therapeutics, including the Chief Financial Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as NovaGo Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- GenSight Biologics raised $1.1M (Post-IPO Equity) on October 16, 2026.
- Estuary Biotherapeutics raised $93M (Series A) on October 16, 2026.
- Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
- Float Bio raised $140K (Pre-Seed) on October 15, 2026.
- Recursion Pharmaceuticals raised $200M (Post-IPO Equity) on October 15, 2026.
- Os Therapies raised $7.2M on October 15, 2026.
Who to call at NovaGo Therapeutics, and when
A new round usually means NovaGo Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day NovaGo Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at NovaGo Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at NovaGo Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment NovaGo Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNovaGo Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.